Laura’s Hair Restore Solution

About Laura's Hair Restoration formula
Minoxidil

When used topically, minoxidil may help stimulate hair growth. Minoxidil may help with various forms of hair loss, including male pattern baldness or hereditary hair loss.[1]

Finasteride

As an oral tablet, finasteride may assist with benign prostate hyperplasia and male pattern hair loss.[2] However, as a topical solution, finasteride may help with male pattern hair loss with potentially less systemic exposure than an oral formulation.[3]

Tretinoin

Commonly, topical tretinoin may be associated with the potential to help acne or aging skin.[4] When combined with minoxidil, studies have suggested tretinoin may also help stimulate hair growth.[5]

Triamcinolone

Triamcinolone belongs to a class of drugs called corticosteroids. It prevents the release of substances in the body that cause inflammation.

Triamcinolone oral (taken by mouth) is used to treat many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.

Minoxidil

The exact mechanism through which minoxidil may help stimulate hair growth is not well understood. Minoxidil may act on certain stages of the hair follicle cell cycle, specifically shortening the telogen (rest) phase and lengthening the anagen (growth) phase. This may help increase hair length and thickness in the applied areas.[1] [6] Minoxidil may also act through other mechanisms to assist with hair growth such as vasodilation. Minoxidil may help increase vasodilation around the hair follicles, which may help improve circulation and thus support hair growth.[1]

Finasteride

Finasteride may help male pattern hair loss by inhibiting the type II and III isoenzymes of the 5a-reductase enzyme. In the body, this 5a-reductase enzyme converts testosterone to dihydrotestosterone (DHT). The type II isoenzyme is present in the outer root sheath of hair follicles, the prostate, and other sites in the male reproductive tract.[2] DHT is more potent than other androgenic hormones because of its high affinity to the androgen receptor.[7] DHT is involved in many areas of sexual development, including maturation of male sexual organs, facial hair, and body and pubic hair. In adulthood, DHT may cause enlargement of the prostate and hair loss in men.7 By blocking the 5a-reductase enzyme, finasteride may help reduce hair loss caused by DHT.[2] [7]

Tretinoin

When used in combination with minoxidil, an in vitro study suggested tretinoin may help activate certain kinase pathways associated with cell growth and survival.[5] Additionally, a study in patients with androgenic alopecia suggested tretinoin may help increase response to topical minoxidil in this patient population. Sharma et al. proposed that topical tretinoin may increase follicular sulfotransferase enzymes in patients with low initial expression. This may help improve response to topical minoxidil in patients with androgenic alopecia who do not respond to minoxidil initially.[8]

Triamcinolone

Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Triamcinolone has intermediate to high range potency (dosage-form dependent).

Minoxidil

Precautions for minoxidil may include heart disease or high blood pressure. Minoxidil may cause adverse cardiac effects if used for extended periods of time or over a large area of skin. Additionally, skin conditions such as irritation or sunburn on the area of application may increase the chance of side effects.[9] After application, ensure product is dry prior to initiating contact with others, as excessive hair growth has been reported in babies after skin contact with treated areas.[1]

Finasteride

Finasteride is contraindicated for use in pregnant women, women who may become pregnant, and children. Finasteride should not be handled by pregnant women or women of childbearing potential due to risk of fetal harm. Patients receiving finasteride therapy should not donate blood during therapy and for 6 months following stopping dutasteride to avoid risk of finasteride exposure to a pregnant transfusion recipient.[2]

In patients with liver disease, finasteride concentrations may be higher due to reduced liver metabolism of the drug.[2]

Tretinoin

Tretinoin may cause increased sensitivity to the sun. Patients using tretinoin should take precautions and wear sunscreen or cover skin with clothing to protect from sun damage. Avoid use of tretinoin if a sunburn or eczema is present to avoid increased risk of irritation. Tretinoin is contraindicated for use during pregnancy.[4]

Disclaimer: Do not take this medication if you are allergic to any components of this product. Stop taking your medicine and seek immediate medical attention if you have any signs of a severe allergic reaction such as but not limited to rash or hives spreading across your body, any swelling of the face, tongue, or throat, or any signs of trouble breathing.

Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also, tell them if you smoke, drink alcohol, or use other drugs. Some items may interact with your medicine. This is not a complete list of key warnings, contraindications and precautions. Reach out to your healthcare provider with any questions.

Triamcinolone

Hypersensitivity to triamcinolone or any component of the formulation

Oral topical formulations only: Fungal, viral, or bacterial infections of the mouth or throat

Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.

• Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.

• Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.

• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.

Older adult: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.

• Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.

• Administration: Aerosol solution: Do not apply to underarms or groin unless directed by a health care professional; if improvement is not seen within 2 weeks, contact prescriber. Product is flammable; avoid heat, smoking, or flames when applying.

Minoxidil

Potential interactions for topical minoxidil may include cyclosporine and aspirin. Cyclosporine may make certain hair growth in unwanted areas worse when used in combination with minoxidil. Low-dose aspirin may reduce the potential effects on hair growth of minoxidil.[1]

Finasteride

Finasteride may cause orthostatic hypotension, especially if combined with alpha blockers, a class of drug used for high blood pressure.[2]

Tretinoin

Topical products that may cause skin dryness and irritation should be avoided in combination with tretinoin. Examples of these may include harsh soaps or shampoos, chemicals to color hair, or other topical products that contain alcohol, astringents, or other ingredients that may irritate the skin.[4]

Disclaimer: This is not a complete list of potential interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also, tell them if you smoke, drink alcohol, or use other drugs. Some items may interact with your medicine. Reach out to your healthcare provider with any questions.

Minoxidil

Potential side effects that may occur with topical minoxidil include hair shedding, skin irritation, itching, or excessive hair growth known as hypertrichosis. Although minoxidil may help stimulate hair growth, its potential effects on the cell cycle may result in hair shedding in some patients. Topical application may cause skin irritation or discomfort that may include redness or a burning sensation on the applied area. Excessive hair growth is also possible with minoxidil.[1]

Finasteride

Finasteride may affect sexual function, which may include decreased sexual desire or erectile dysfunction. Finasteride may also affect sperm count and semen volume, which may lead to infertility.[2]

Due to finasteride’s potential to inhibit the 5-alpha reductase enzyme, testosterone may be eliminated through other pathways. This may lead to increased estrogen levels which may cause other adverse effects such as gynecomastia.[2] [7]

Other potential side effects may include dizziness, weakness, shortness of breath, or rash.[2]

Tretinoin

When applied topically, tretinoin may cause itching, skin irritation, redness, or skin pain. Tretinoin may also increase sensitivity to the sun. Take care and wear sunscreen or protective clothing if sun exposure cannot be avoided while using tretinoin.[4]

Disclaimer: This is not a complete list of side effects. Please call your healthcare provider if you experience any unusual side effects or have any questions.

Triamcinolone

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for topical triamcinolone.

Frequency not defined:

Dermatologic: Acneiform eruption, allergic contact dermatitis, atrophic striae, desquamation, folliculitis, hypertrichosis, hypopigmentation, local dryness, maceration of the skin, miliaria, perioral dermatitis, skin atrophy, skin blister

Endocrine & metabolic: Cushing syndrome, glycosuria, HPA-axis suppression, hyperglycemia

Gastrointestinal: Oral mucosa changes (paste; atrophy or maceration)

Infection: Secondary infection

Local: Application site burning, application site irritation, application site pruritus

Minoxidil

Minoxidil is not recommended for use in patients who are pregnant or breastfeeding. Minoxidil may cause birth defects in unborn infants if administered to a pregnant woman.[1] Minoxidil may be excreted into breast milk.[10]

Finasteride

Finasteride is contraindicated in pregnant women as it may cause harm to the unborn child. Pregnant women or women who may be pregnant should not handle finasteride formulations due to risk for potential skin absorption. It is unknown if finasteride passes into breast milk and should not be used during breastfeeding.[2]

Tretinoin

Tretinoin is contraindicated for use during pregnancy. There is a high risk of pregnancy loss and birth defects if tretinoin is administered during pregnancy. It is unknown if tretinoin passes into breast milk, but due to potentially serious risk tretinoin should not be used in breast-feeding women.[4]

Disclaimer: Tell your healthcare provider if you are pregnant, planning to become pregnant, or are breast-feeding prior to taking this formulation.

Triamcinolone

Pregnancy Considerations

Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes; however, there may be an increased risk of low birth-weight infants following maternal use of potent or very potent topical products, especially in high doses, although this risk is likely to be low (Andersson 2021; Chi 2015; Chi 2017).

When first-line treatments, such as emollients, are insufficient, topical corticosteroids may be used for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019). Topical corticosteroids are classified by potency; the medication and formulation (eg, cream, gel, and/or salt form) contribute to the potency classification (Oakley 2021; Stacey 2021; Tadicherla 2009). In general, use of the least potent product in limited amounts is recommended during pregnancy. Mild to moderate potency corticosteroids are preferred; potent to very potent topical corticosteroids should only be used as alternative therapy in limited amounts under obstetrical care. Pregnant patients should avoid application of topical corticosteroids to areas with high percutaneous absorption (eg, armpit, skin folds, vulva) (Chi 2017) and caution should be used when applying to areas prone to striae formation (eg, abdomen, breast, thighs) (Vestergaard 2019).

Breastfeeding Considerations

It is not known if sufficient quantities of triamcinolone are absorbed following topical administration to produce detectable amounts in breast milk; however, systemic corticosteroids are present in breast milk.

Although the manufacturer recommends that caution be used, topical corticosteroids are generally considered acceptable for use in patients who are breastfeeding (Butler 2014; WHO 2002).

Avoid application of topical corticosteroids to the nipple and areola area until breastfeeding ceases; hypertension was noted in a breastfed infant when a high-potency topical corticosteroid was applied to the nipple (AAD-NPF [Elmets 2021]; Butler 2014; Leachman 2006). If needed, apply topical corticosteroids immediately after breastfeeding then clean nipples prior to the next feeding (Vestergaard 2019).

Store between 68°F to 77°F (20°C – 25°C). Properly discard any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain. Keep all medicine out of the reach of children and pets.

  1. Patel P, Nessel TA, Kumar D D. Minoxidil. [Updated 2023 Feb 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482378/– LinkOpens in New Tab
  2. Zito PM, Bistas KG, Patel P, et al. Finasteride. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513329/– LinkOpens in New Tab
  3. Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, Tamarit ML, Galván J, Tebbs V, Massana E; Topical Finasteride Study Group. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286-294. doi: 10.1111/jdv.17738. Epub 2021 Oct 25. Erratum in: J Eur Acad Dermatol Venereol. 2023 Feb;37(2):452. doi: 10.1111/jdv.18750. PMID: 34634163; PMCID: PMC9297965.
  4. Yoham AL, Casadesus D. Tretinoin. [Updated 2023 Mar 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557478/– LinkOpens in New Tab
  5. Kwon OS, Pyo HK, Oh YJ, Han JH, Lee SR, Chung JH, Eun HC, Kim KH. Promotive effect of minoxidil combined with all-trans retinoic acid (tretinoin) on human hair growth in vitro. J Korean Med Sci. 2007 Apr;22(2):283-9. doi: 10.3346/jkms.2007.22.2.283. PMID: 17449938; PMCID: PMC2693596.
  6. Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499948/– LinkOpens in New Tab
  7. Kinter KJ, Amraei R, Anekar AA. Biochemistry, Dihydrotestosterone. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557634/– LinkOpens in New Tab
  8. Sharma A, Goren A, Dhurat R, Agrawal S, Sinclair R, Trüeb RM, Vañó-Galván S, Chen G, Tan Y, Kovacevic M, Situm M, McCoy J. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019 May;32(3):e12915. doi: 10.1111/dth.12915. Epub 2019 Apr 23. PMID: 30974011.
  9. “Minoxidil (Topical Route).” Mayo Clinic, Mayo Foundation for Medical Education and Research, www.mayoclinic.org/drugs-supplements/minoxidil-topical-route/description/drg-20068750#drug-precautions Accessed 21 Nov. 2024.
    1. Valdivieso A, Valdés G, Spiro TE, Westerman RL. Minoxidil in breast milk. Ann Intern Med. 1985 Jan;102(1):135. doi: 10.7326/0003-4819-102-1-135_1. PMID: 396673

  10. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.[PubMed 3960626]

    Altenburg A, El-Haj N, Micheli C, Puttkammer M, Abdel-Naser MB, Zouboulis CC. The treatment of chronic recurrent oral aphthous ulcers. Dtsch Arztebl Int. 2014;111(40):665-673. doi: 10.3238/arztebl.2014.0665.[PubMed 25346356]

    American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology. Contact dermatitis: a practice parameter [published correction appears in Ann Allergy Asthma Immunol. 2006;97(6):819]. Ann Allergy Asthma Immunol. 2006;97(3)(suppl 2):S1-S38.[PubMed 17039663]

    American Academy of Pediatrics Committee on Drugs. “Inactive” ingredients in pharmaceutical products: update (subject review). Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

    Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. JAMA Dermatol. 2021. doi:10.1001/jamadermatol.2021.1090[PubMed 33950165]

    Brod BA. Management of allergic contact dermatitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 31, 2023.

    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70(3):417. doi:10.1016/j.jaad.2013.09.009[PubMed 24528912]

    Buys LM. Treatment options for atopic dermatitis. Am Fam Physician. 2007;75(4):523-528.[PubMed 17323714]

    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199.http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm[PubMed 6423951]

    Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. J Eur Acad Dermatol Venereol. 2017;31(5):761-773. doi:10.1111/jdv.14101[PubMed 28233354]

    Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;(10):CD007346. doi:10.1002/14651858.CD007346.pub3[PubMed 26497573]

    Dermasorb TA (triamcinolone acetonide) [prescribing information]. Johnson City, TN: Crown Laboratories, Inc.

    Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(5, pt 1):824-829.[PubMed 8632081]

    Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi: 10.1016/j.jaad.2014.03.023.[PubMed 24813302]

    Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087[PubMed 32738429]

    Feldman SR. Treatment of psoriasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 25, 2021.

    Fransway AF and Fowler J. Irritant contact dermatitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 31, 2023.

    Fransway AF. Stasis dermatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 10, 2019.

    Goldstein BG, Goldstein AO. General principles of dermatologic therapy and topical corticosteroid use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 8, 2019.

    Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1-191.[PubMed 11134919]

    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.[PubMed 12534540]

    Johnson NR, Scheinman PL, Watson AJ. Vulvar dermatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 26, 2021.

    Kenalog spray (triamcinolone acetonide) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; November 2017.

    Kourzeq (triamcinolone) [prescribing information]. Oak Park, IL: MidAmerica Pharmaceuticals LLC; October 2022.

    Lau CB, Smith GP. Recurrent aphthous stomatitis: a comprehensive review and recommendations on therapeutic options. Dermatol Ther. 2022;35(6):e15500. doi:10.1111/dth.15500[PubMed 35395126]

    Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006;24(2):167-197, vi. doi:10.1016/j.det.2006.01.001[PubMed 16677965]

    Lewis-Jones S, Mugglestone MA, Guideline Development Group. Management of atopic eczema in children aged up to 12 years: summary of NICE guidance. BMJ. 2007;335(7632):1263-1264.[PubMed 18079551]

    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.[PubMed 10985636]

    McBride DR. Management of aphthous ulcers. Am Fam Physician. 2000;62(1):149-154, 160.[PubMed 10905785]

    Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191.[PubMed 32265601]

    Oakley R, Arents BWM, Lawton S, Danby S, Surber C. Topical corticosteroid vehicle composition and implications for clinical practice. Clin Exp Dermatol. 2021;46(2):259-269. doi:10.1111/ced.14473[PubMed 33108015]

    Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013;168(5):954-967. doi: 10.1111/bjd.12276.[PubMed 23413913]

    Sasseville D. Seborrheic dermatitis in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 8, 2020.

    Savas JA, Pichardo RO. Female genital itch. Dermatol Clin. 2018;36(3):225-243. doi: 10.1016/j.det.2018.02.006.[PubMed 29929595]

    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259.[PubMed 19188870]

    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8960):1312-1313.[PubMed 7746084]

    Stacey SK, McEleney M. Topical corticosteroids: choice and application. Am Fam Physician. 2021;103(6):337-343.[PubMed 33719380]

    Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009;8(12):1093-1105.[PubMed 20027937]

    Taylor J, Glenny AM, Walsh T, et al. Interventions for the management of oral ulcers in Behçet’s disease. Cochrane Database Syst Rev. 2014;(9):CD011018. doi: 10.1002/14651858.CD011018.pub2.[PubMed 25254615]

    Triamcinolone acetonide cream [prescribing information]. Bronx, NY: Perrigo; March 2022.

    Triamcinolone acetonide dental paste [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals USA Inc; August 2006.

    Triamcinolone acetonide lotion [prescribing information]. West Caldwell, NJ: Quagen Pharmaceuticals LLC; July 2020.

    Triamcinolone acetonide lotion [prescribing information]. Marietta, GA: VersaPharm Incorporated; May 2013.

    Triamcinolone acetonide ointment [prescribing information]. Princeton, NJ: Macleods Pharma USA Inc; July 2023.

    Trianex (triamcinolone) [prescribing information]. Farmville, NC: CMP Pharma, Inc; July 2019.

    Triderm (triamcinolone acetonide) [prescribing information]. Johnson City, TN: Crown Laboratories; September 2017.

    Tritocin (triamcinolone acetonide) [prescribing information]. Wilmington, DE: Eckson Labs; April 2021.

    van der Meijden WI, Boffa MJ, Ter Harmsel B, et al. 2021 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2022;36(7):952-972. doi:10.1111/jdv.18102[PubMed 35411963]

    Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659. doi:10.1111/jdv.15709[PubMed 31231864]

    Weston WL, Howe W. Treatment of atopic dermatitis (eczema). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 23, 2021.

    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/